“Immune Checkpoint Inhibitors in Advanced Lung Cancer: Safety Profile and Importance of Early Diagnosis and Treatment of Immune-Related Adverse Events”

https://pubmed.ncbi.nlm.nih.gov/38095153

This study of 78 patients with advanced metastatic lung cancer found that while immune checkpoint inhibitors had an acceptable overall safety profile, immune-related adverse events (irAEs) occurred in 20 patients, including severe cardiotoxicity, and early diagnosis and treatment of irAEs is crucial due to the high mortality risk of severe irAEs.